LexDanaLexDanabeta
Inventor

Abraham Bout

Inventor
Moerkapelle, NL

Overview

55→
Patents
1999–2021
Patent span
Chemistry
Primary field (CPC C)

Patents· 55 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Nprimary
C12NMicroorganisms or enzymes27%
A61KPreparations for medical, dental or toiletry purposes24%
C07KPeptides22%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations15%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture7%
Y02PClimate change mitigation technologies in the production or processing of goods4%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
10,934,571Recombinant production of mixtures of antibodies202110,562,956Recombinant fibrinogen2020RE047770Recombinant production of mixtures of antibodies201910,004,787Fibrinogen preparations enriched in fibrinogen with an extended alpha chain20189,694,054'Fibrinogen preparations enriched in fibrinogen with an extended alpha chain'20179,303,081'Recombinant production of mixtures of antibodies'20168,236,561'Efficient production of IgA in recombinant mammalian cells'20128,236,293'Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer'20128,221,971'Serotype of adenovirus and uses thereof'20127,968,087'Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells'20117,932,360'Recombinant production of mixtures of antibodies'20117,927,834'Recombinant production of mixtures of antibodies'20117,906,113'Serotype of adenovirus and uses thereof'20117,820,440'Means and methods for producing adenovirus vectors'20107,785,833'Methods and means for producing proteins with predetermined post-translational modifications'20107,749,493'Chimeric adenoviruses'20107,696,157'Methods and means for producing proteins with predetermined post-translational modifications'20107,537,916'Efficient production of F(ab\')2 fragments in mammalian cells'20097,491,532'Recombinant protein production in a human cell'20097,470,523'Recombinant protein production in a human cell'20087,468,181'Means and methods for the production of adenovirus vectors'20087,429,486'Recombinant production of mixtures of antibodies'20087,304,031'Methods and means for producing proteins with predetermined post-translational modifications'20077,270,811'Serotype of adenovirus and uses thereof'20077,262,028'Recombinant production of mixtures of antibodies'20077,238,528'Means and methods for fibroblast-like or macrophage-like cell transduction'20077,235,233'Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts'20077,132,280'Recombinant protein production in a human cell'20067,105,346'Packaging systems for human recombinant adenovirus to be used in gene therapy'20067,052,881'Packaging systems for human recombinant adenovirus to be used in gene therapy'20067,037,716'Packaging systems for human recombinant adenovirus to be used in gene therapy'20067,029,848'High throughput screening of gene function using libraries for functional genomics applications'20066,929,946'Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells'20056,913,922'Serotype of adenovirus and uses thereof'20056,905,678'Gene delivery vectors with cell type specificity for mesenchymal stem cells'20056,878,549'Packaging systems for human recombinant adenovirus to be used in gene therapy'20056,869,936'Means and methods for fibroblast-like or macrophage-like cell transduction'20056,855,544'Recombinant protein production in a human cell'20056,803,234'Gene delivery vectors with cell type specificity for primary human chondrocytes'20046,783,980'Packaging systems for human recombinant adenovirus to be used in gene therapy'20046,692,966'Packaging systems for human recombinant adenovirus to be used in gene therapy'20046,670,188'Packaging systems for human recombinant adenovirus to be used in gene therapy'20036,602,706'Packaging systems for human recombinant adenovirus to be used in gene therapy'20036,495,131'Interleukin-3 gene therapy for cancer'20026,413,776'High throughput screening of gene function using adenoviral libraries for functional genomics applications'20026,395,519'Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer'20026,340,595'High throughput screening of gene function using adenoviral libraries for functional genomics applications'20026,306,652'Packaging systems for human recombinant adenovirus to be used in gene therapy'20016,303,300'Poly (organo) phosphazenes for use in synthetic transfection systems'20016,265,212'Packaging systems for human recombinant adenovirus to be used in gene therapy'20016,238,893'Method for intracellular DNA amplification'20016,204,052'Adenoviral vectors with reduced TNF response and partial E3 region deletion'20016,033,908'Packaging systems for human recombinant adenovirus to be used in gene therapy'20005,994,128'Packaging systems for human recombinant adenovirus to be used in gene therapy'19995,914,231'Poly(organo)phosphazenes for use in synthetic transfection systems'1999

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1999–2005Patents assigned to INTROGENE BV (10)· patent assignee history
1999–2020Based in Moerkapelle, NL· patent location history
2001Based in Moenkepelle, NL· patent location history
2002–2012Patents assigned to CRUCELL HOLLAND BV (33)· patent assignee history
2011–2016Patents assigned to MERUS B V (3)· patent assignee history
2012–2016Patents assigned to BOUT ABRAHAM (4)· patent assignee history
2016–2021Based in Leiden, NL· patent location history
2017–2020Patents assigned to MALLINCKRODT PHARMA IP TRADING D A C (3)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
CRUCELL HOLLAND BV332002–2012
INTROGENE BV101999–2005
BOUT ABRAHAMself42012–2016
MALLINCKRODT PHARMA IP TRADING D A C32017–2020
MERUS B V32011–2016
Locations
LocationPatentsSpan
Moerkapelle, NL511999–2020
Leiden, NL32016–2021
Moenkepelle, NL12001